Valneva (NASDAQ:VALN) Shares Down 5.6% – Time to Sell?

Valneva SE (NASDAQ:VALN) shares were down 5.6% during trading on Friday . The company traded as low as $6.55 and last traded at $6.54. Approximately 19,989 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 54,825 shares. The stock had previously closed at $6.93.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Valneva in a research note on Friday, January 31st.

Valneva Trading Down 6.4 %

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average price of $4.52 and a two-hundred day moving average price of $5.66. The firm has a market capitalization of $526.97 million, a price-to-earnings ratio of -50.08 and a beta of 1.98.

Institutional Trading of Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new position in shares of Valneva SE (NASDAQ:VALN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.